Please note that IPD sharing statement and summary results sections will be added to the ANZCTR form in the coming weeks in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Trial ID
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Effect of Rosiglitazone on Bone Metabolism
Scientific title
A three month randomised, double-blind, placebo-controlled trial to determine the effect of rosiglitazone on bone and calcium metabolism in normal post menopausal women.
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Normal Post Menopausal Women 301 0
Condition category
Condition code
Reproductive Health and Childbirth 344 344 0 0
Menstruation and menopause

Study type
Description of intervention(s) / exposure
8mg rosiglitazone daily over 3 months
Intervention code [1] 221 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 399 0
Change in bone turnover markers in the rosiglitazone group compared to the change in the control group over 3 months
Timepoint [1] 399 0
3 months
Secondary outcome [1] 869 0
Not applicable
Timepoint [1] 869 0
Not applicable

Key inclusion criteria
Postmenopausal 5 yrs or more.
Minimum age
Not stated
Maximum age
Not stated
Can healthy volunteers participate?
Key exclusion criteria
Renal impairment (serum creatinine >0.15 mmol/L), congestive heart failure, chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness, malignancy, active major gastrointestinal disease, metabolic bone diseases, or serum ALP > 2x normal limit, diabetes mellitus, primary hyperparathyroidism, > 2 hospital admission within 6 months of study entry. Use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2.5 mg/day in the preceding 12 months, current or past use of bisphosphonate therapy, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism, current or past use of thiazolidinediones.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Medication was dispensed by a doctor not involved with study participants into numbered containers. All study personnel with patient contact were blinded.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random numbers in variable blocks.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 141 0
New Zealand
State/province [1] 141 0

Funding & Sponsors
Funding source category [1] 404 0
Government body
Name [1] 404 0
Health Research Council of New Zealand
Address [1] 404 0
Level 3, 110 Stanley Street, Auckland, New Zealand
Country [1] 404 0
New Zealand
Primary sponsor type
Associate Professor A Grey
Bone Research Group Department of Medicine Auckland University Private Bag 92 019 Auckland 1020
New Zealand
Secondary sponsor category [1] 327 0
Name [1] 327 0
University of Auckland Bone Research Group
Address [1] 327 0
Bone Research Group Department of Medicine Auckland University Private Bag 92 019 Auckland 1020
Country [1] 327 0
New Zealand

Ethics approval
Ethics application status
Ethics committee name [1] 1389 0
Auckland University
Ethics committee address [1] 1389 0
Ethics committee country [1] 1389 0
Date submitted for ethics approval [1] 1389 0
Approval date [1] 1389 0
Ethics approval number [1] 1389 0

Brief summary
This is a 3 month study designed to determine the effect of rosiglitazone on bone metabolism
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 35397 0
Address 35397 0
Country 35397 0
Phone 35397 0
Fax 35397 0
Email 35397 0
Contact person for public queries
Name 9410 0
Diana Wattie
Address 9410 0
Bone Research Group
Department of Medicine
Auckland University
Private Bag 92 019
Auckland 1020
Country 9410 0
New Zealand
Phone 9410 0
+64 9 3078970
Fax 9410 0
+64 9 3737677
Email 9410 0
Contact person for scientific queries
Name 338 0
Associate Professor Grey
Address 338 0
Bone Research Group
Department of Medicine
Auckland University
Private Bag 92 019
Auckland 1020
Country 338 0
New Zealand
Phone 338 0
+64 9 3737599
Fax 338 0
+64 9 3737677
Email 338 0